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Stabilization of Microcirculation in Patients with Early
Systemic Sclerosis with Diffuse Skin Involvement following
Rituximab Treatment: An Open-label Study
To the Editor:
Systemic sclerosis (SSc) is a multisystemic autoimmune disease charac-
terized by fibrosis of the skin and internal organs, generalized microvascu-
lopathy, and antibody response against various cellular antigens. Severe
organ involvement occurs early in the course of diffuse cutaneous SSc
(dcSSc) and has a bad prognosis1. Survival of the first years of the disease
is associated with improved outcome. Therapies that may help the patient
overcome this early period seem warranted2. Rituximab (RTX) has been
reported as optional therapy in SSc3,4,5. Our group reported stabilization of
internal organ involvement during a 2-year followup in an open pilot study
of a 2–treatment course (months 0 and 6) of RTX in patients with early
dcSSc6,7. In our pilot studies, modified Rodnan skin score (mRSS) decreased
significantly after RTX course. The percent of decrease in the open pilot
studies was corroborated by a similar decrease in the percentage of collagen
score in blindly assessed histopathological skin analyses.
Because SSc is characterized by a pronounced microangiopathy over
time (i.e., more severe loss of capillaries over time), it may be worthwhile
to investigate whether treatment with RTX could also stabilize micro-
angiopathy in dcSSc8,9. Nailfold videocapillaroscopy (NVC) is a reliable
technique to evaluate the microcirculation (capillaries) in SSc10. Subsequent
to the former studies, our additional study described herein, using the same
design as the already published studies, is the first (to our knowledge) to
assess microangiopathic evolution after a 2-treatment course (months 0 and
6) with RTX in early dcSSc6,7. Six consecutive patients with “early” (see
below) dcSSc received an infusion of 2 times 1000 mg RTX at months 0
and 6, together with 100 mg methylprednisolone. Low-dose prednisolone
(≤ 10 mg/day) was allowed, provided that the patients were taking a stable
dose at least 12 weeks before inclusion in the trial. All disease-modifying
antirheumatic drugs [except methotrexate (MTX)] were stopped 12 weeks
before screening6,7. Patients (5 men and 1 woman) were receiving a stable
dose of MTX (10–25 mg/week) as background therapy since at least 12
weeks. Their median age was 49 years (range 37–64 yrs) and their median
SSc disease duration was 11 months (range 5–22 mos, from onset of the first
non-Raynaud phenomenon). Four of the 6 patients were anti-scl70–positive
and 1/6 was RNA-polymerase–positive.
Nailfold capillaries were imaged using a nailfold videocapillaroscope
with high magnification (200×) in 8 fingers (f), f2–5 of both hands, at
months 0, 3, 6, and 12. The number of capillaries in the distal row were
recorded, as well as the number of giants and hemorrhages, and the number
of abnormally shaped [(neo)angiogenetic] capillaries. Scores were calcu-
lated, as described previously9. The observers evaluating the capillaroscopic
images (CP, VR) were blinded to the study design and subjects’ identity.
Next to capillaroscopic assessment, clinical readouts (mRSS, lung function,
and echocardiography) and Disease Activity Score (DAS) were done at 0,
3, 6, and 12 months6,7. Mixed-model analysis (MMA) with random intercept
for patient was used to evaluate changes in variables over time. A statistical
significance level of 0.05 was used.
There was a clinical significant change in skin score with a mean (SD)
mRSS of 24.8 (5.95) at baseline and 10.2 (1.17) at Month 12 (MMA p <
0.001, mean/median % improvement: 59%/60%) and a significant decrease
in DAS, with a mean (SD) of 4.2 (1.69) at baseline and 0.6 (0.74) at Month
12 (MMA p < 0.001, mean/median % improvement: 86%/87%). Indices of
internal organ involvement remained stable (Table 1).
Semiquantitatively scored NVC variables remained stable, showing no
progression of the microvascular damage during the 12-month followup
(Table 2)9. More specifically, whereas more pronounced loss of capillaries
was expected over time, the number of capillaries remained stable8. In this
way, the mean score (SD) of capillary loss at baseline/12 months was 2.170
(0.408)/1.830 (0.408, MMA p = 0.341). There was also no significant change
in the number of other scleroderma type morphological characteristics
(giants, hemorrhages, and neoangiogenesis) over time (Table 2). There was
1 serious adverse event, a scleroderma renal crisis. It occurred before the
first RTX infusion and was considered probably unrelated to the study
medication. It reacted well to angiotensin-converting enzyme inhibitors
without need for renal replacement therapy, further bouts, or deterioration
during the 12-month followup.
To our knowledge, ours is the first open pilot study to suggest that 2
immunosuppressive treatment courses with RTX, while receiving
background stable MTX, may not only have potential efficacy for skin and
stabilization of internal organ involvement, but also additional stabilization
of microangiopathic variables in early dcSSc. Larger, randomized controlled
trials are needed to further investigate these findings.
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Table 1. Changes in clinical variables in patients with early and severe diffuse cutaneous systemic sclerosis treated with rituximab (n = 6). Data are mean (SD),
median (IQR).
0M 3M p* 6M p* 12M p* p MMA
mRSS, 0–51 points 24.8 (5.95) 18.6 (8.68) 0.026 13.8 (5.19) < 0.001 10.2 (1.17) < 0.001 < 0.001
25.0 (19.3–30.0) 15.0 (12.5–26.5) 13.5 (8.8–19.3) 10.0 (9.0–11.3)
DLCO, % of normal 70.2 (12.98) 61.0 (12.21) 0.105 66.5 (15.98) 0.213 69.3 (18.13) 0.771 0.302
68.0 (59.8–85.0) 61.0 (51.0–71.0) 67.0 (57.5–75.3) 69.5 (59.0–83.8)
FVC, % of normal 99.7 (13.77) 94.4 (11.08) 0.590 100.5 (17.74) 0.808 101.2 (13.85) 0.646 0.781
99.0 (88.8–113.3) 97.0 (84.0–103.5) 100.5 (86.0–116.0) 105.5 (91.0–111.5)
TLC, % of normal 87.5 (9.40) 83.8 (9.52) 0.970 88.7 (15.74) 0.740 94.5 (14.6) 0.062 0.191
87.0 (78.0–94.8) 81.0 (76.5–92.5) 85.0 (78.3–103.8) 94.0 (83.8–104.5)
FEV, % of normal 92.5 (10.15) 91.0 (12.02) 0.447 91.8 (12.29) 0.796 97.3 (11.76) 0.077 0.088
90.0 (83.5–104.3) 95.0 (78.5–101.5) 95.0 (79.3–101.0) 98.0 (87.5–107.0)
DAS, 0–10 points 4.2 (1.69) 1.8 (1.15) < 0.001 1.1 (0.58) < 0.001 0.6 (0.74) < 0.001 < 0.001
3.8 (3.1–5.5) 2.0 (0.8–2.8) 1.0 (0.5–1.6) 0.5 (0.0–0.9)
sPAP, mmHg 30.5 (2.65) 30.4 (6.19) 0.581 33.0 (8.25) 0.734 30.4 (4.45) 0.430 0.603
31.0 (27.8–32.8) 28.0 (25.5–36.5) 32.0 (25.5–41.0) 29.0 (26.5–35.0)
LVEF, % of normal 58.5 (8.10) 65.8 (7.82) 0.094 59.5 (4.93) 0.830 63.5 (5.72) 0.239 0.238
57.5 (51.3–66.8) 69.0 (58.0–72.0) 59.0 (55.0–63.3) 64.0 (58.8–69.0)
* Significance of all values versus baseline. M: month; MMA: mixed-model analysis; mRSS: modified Rodnan skin score; FVC: forced vital capacity; TLC:
lung total capacity; FEV: forced expiratory volume; DAS: Disease Activity Score; sPAP: systolic pulmonary artery pressure; LVEF: left ventricular ejection
fraction; IQR: interquartile range.
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Table 2. Microangiopathic evolution (SQ scores) in patients with early and severe diffuse cutaneous systemic sclerosis treated with rituximab (n = 6). Data are
mean (SD), median (IQR).
0M 3M p* 6M p* 12M p* p MMA
SQ capillary loss 2.17 (0.408) 2.20 (0.447) 0.915 2.17 (0.753) 1.000 1.83 (0.408) 0.147 0.341
2.0 (2.0–2.3) 2.0 (2.0–2.5) 2.0 (1.8–3.0) 2.0 (1.8–2.0)
SQ giants 0.67 (0.516) 1.00 (0.000) 0.122 1.00 (0.000) 0.090 1.17 (0.408) 0.016 0.093
1.0 (0.0–1.0) 1.0 (0.0–1.0) 1.0 (0.0–1.0) 1.0 (1.0–1.3)
SQ hemorrhages 0.67 (0.516) 0.80 (0.447) 0.590 0.83 (0.408) 0.463 1.00 (0.000) 0.154 0.529
1.0 (0.0–1.0) 1.0 (0.5–1.0) 1.0 (0.8–1.0) 1.0 (0.0–1.0)
SQ neoangiogenesis 0.83 (0.408) 1.20 (1.095) 0.132 1.00 (0.632) 0.573 0.83 (0.753) 1.000 0.383
1.0 (0.8–1.0) 1.00 (0.5–2.0) 1.00 (0.8–1.3) 1.00 (0.0–1.3)
* P value versus baseline. SQ: semiquantitative; M: month; MMA: mixed-model analysis; IQR: interquartile range.
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